Oncosec Medical Inc (ONCS) 5.75 $ONCS
OncoSec Medical Inc. (Nasdaq: ONCS) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Mon Jul 06, 9:00AM CDT
What:
ONCS: 5.75 (-0.06), NDAQ: 50.48 (+1.26)
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
PR Newswire - Mon Jul 06, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Joann V. Lofgren to the newly created position of Vice President of Market Development, effective July 6, 2015. In this role, Ms. Lofgren will be responsible for evaluating, designing, and executing on the company's market and product development strategy for all therapeutic products.
ONCS: 5.75 (-0.06)
OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell
PR Newswire - Wed Jul 01, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (Nasdaq: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that CEO and President Punit Dhillon will ring The Nasdaq Opening Bell in celebration of the Company's listing to The Nasdaq Stock Market at 9:30 am ET on July 7, 2015 at The Nasdaq MarketSite in New York City.
ONCS: 5.75 (-0.06)
OncoSec Medical Appoints Richard B. Slansky as Chief Financial Officer
PR Newswire - Thu Jun 25, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Richard B. Slansky as the Company's Chief Financial Officer, effective July 6, 2015. Mr. Slansky is responsible for leading financial operations and activities for OncoSec as well as managing financial plans and budgets. Veronica Vallejo, the current Chief Financial Officer of OncoSec, resigned from her position effective June 24, 2015 to pursue other opportunities.
ONCS: 5.75 (-0.06)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 11:40AM CDT
ACHC: 80.58 (+1.02), SGNL: 1.98 (-0.01), PRGO: 180.86 (+0.85), ESPR: 90.01 (+1.32), RXDX: 15.42 (+0.25), BAX: 37.61 (+0.59), UNH: 122.15 (+2.81), ONCS: 5.75 (-0.06), CVRS: 3.59 (-0.18), EGRX: 85.26 (+4.84), CASI: 1.70 (+0.05), PCRX: 67.54 (+0.20), BLRX: 2.29 (+0.05)
OncoSec Medical Incorporated: The Best Immuno-Oncology Biotech You've Never Heard Of
Stock Doctor - Seeking Alpha - Wed Jun 24, 10:39AM CDT
My investment strategy is simple. Find small-cap undervalued biotech companies with promising drugs and significant short and long term upside. My last article published a couple weeks ago detailed Tokai Pharmaceuticals (NASDAQ: TKAI ) and why its...
MRK: 57.95 (+0.57), ONCS: 5.75 (-0.06), BMY: 69.27 (+1.38)
OncoSec Medical Issues Annual Letter To Shareholders
PR Newswire - Wed Jun 17, 3:50PM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today issued the following letter from Punit Dhillon, President and CEO of OncoSec, to the company's shareholders. The letter and supplemental proxy information are available by clicking here.
ONCS: 5.75 (-0.06)
OncoSec Medical Enrolls First Patient in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial
PR Newswire - Tue Jun 16, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse(TM) IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC). ImmunoPulse(TM) IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to promote an anti-tumor immune response.
ONCS: 5.75 (-0.06)
OncoSec Medical Set to Join Russell Microcap Index
PR Newswire - Mon Jun 15, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it is set to join the Russell Microcap Index at the conclusion of the Russell indexes annual reconstitution on June 26, according to a preliminary list of additions posted on June 12.
ONCS: 5.75 (-0.06)
OncoSec Medical incurs higher net loss of USD14.7m for nine months fiscal year end 2015
M2 - Wed Jun 10, 3:48AM CDT
Cancer immunotherapies company OncoSec Medical (NasdaqCM:ONCS) stated on Monday its net loss of USD14.7m (USD1.19 per share) for the nine months ended 30 April 2015.
ONCS: 5.75 (-0.06)
OncoSec Medical reports 9M15 results
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 5:25AM CDT
ONCS: 5.75 (-0.06)
OncoSec Medical reports Q1 results
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 5:06AM CDT
ONCS: 5.75 (-0.06)
OncoSec Medical Announces Nine Months Results for Fiscal Year End 2015
PR Newswire - Tue Jun 09, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015.
ONCS: 5.75 (-0.06)
OncoSec Medical concludes USD13.6m in registered direct offering
M2 - Tue Jun 09, 4:40AM CDT
Biopharmaceutical company OncoSec Medical (NasdaqCM:ONCS) reported on Monday the completion of its registered direct offering of 2,469,091 shares of its common stock.
ONCS: 5.75 (-0.06)
OncoSec Medical Closes $13.6 Million Registered Direct Offering
PR Newswire - Mon Jun 08, 4:27PM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced registered direct offering of 2,469,091 shares of its common stock at a price of $5.50 per share on June 8, 2015.
ONCS: 5.75 (-0.06)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
OncoSec Medical to Present at the BIO International Convention
PR Newswire - Thu Jun 04, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at the BIO International Convention on Wednesday, June 17 in Philadelphia. The presentation is scheduled to begin at 11:15 AM ET in Theater 4 at the Pennsylvania Convention Center.
ONCS: 5.75 (-0.06)
OncoSec Medical anticipates USD13.6m from registered direct offering
M2 - Thu Jun 04, 3:12AM CDT
OncoSec Medical (NasdaqCM:ONCS), a biopharmaceutical company developing its investigational ImmunoPulseTM intratumoral cancer immunotherapy, announced on Wednesday that it has entered into definitive agreements to raise about USD13.6m of securities in a registered direct offering.
ONCS: 5.75 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 11:45AM CDT
JRJC: 4.74 (-0.01), GLMD: 10.04 (+0.18), ESI: 3.81 (+0.04), LPTH: 1.90 (-0.01), GEVO: 2.71 (+0.26), ARDX: 17.67 (+1.21), VLTC: 4.77 (+0.11), MIND: 4.14 (-0.03), VISN: 11.82 (+1.83), EMITF: 1.35 (+0.02), STDY: 4.97 (+0.21), CPXX: 2.13 (+0.01), PXLW: 5.53 (+0.20), NOR: 0.52 (-0.07), FWM: 3.29 (-0.03), HTGM: 11.64 (-0.14), ONCS: 5.75 (-0.06), CBAY: 2.68 (-0.01), BLFS: 2.00 (-0.03), HQCL: 14.33 (-0.01)
OncoSec Medical Announces $13.6 Million Registered Direct Offering
PR Newswire - Wed Jun 03, 8:42AM CDT
OncoSec Medical Inc. ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has entered into definitive agreements with dedicated healthcare institutional investors to purchase approximately $13.6 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 2,469,091 shares of its common stock at a price of $5.50 per share.
ONCS: 5.75 (-0.06)
OncoSec Medical Inc. (Nasdaq: ONCS) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Mon Jul 06, 9:00AM CDT
What:
ONCS: 5.75 (-0.06), NDAQ: 50.48 (+1.26)
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
PR Newswire - Mon Jul 06, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Joann V. Lofgren to the newly created position of Vice President of Market Development, effective July 6, 2015. In this role, Ms. Lofgren will be responsible for evaluating, designing, and executing on the company's market and product development strategy for all therapeutic products. ONCS: 5.75 (-0.06)
OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell
PR Newswire - Wed Jul 01, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(Nasdaq: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that CEO and President Punit Dhillon will ring The Nasdaq Opening Bell in celebration of the Company's listing to The Nasdaq Stock Market at 9:30 am ET on July 7, 2015 at The Nasdaq MarketSite in New York City. ONCS: 5.75 (-0.06)
OncoSec Medical Appoints Richard B. Slansky as Chief Financial Officer
PR Newswire - Thu Jun 25, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Richard B. Slansky as the Company's Chief Financial Officer, effective July 6, 2015. Mr. Slansky is responsible for leading financial operations and activities for OncoSec as well as managing financial plans and budgets. Veronica Vallejo, the current Chief Financial Officer of OncoSec, resigned from her position effective June 24, 2015 to pursue other opportunities. ONCS: 5.75 (-0.06)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 11:40AM CDT
ACHC: 80.58 (+1.02), SGNL: 1.98 (-0.01), PRGO: 180.86 (+0.85), ESPR: 90.01 (+1.32), RXDX: 15.42 (+0.25), BAX: 37.61 (+0.59), UNH: 122.15 (+2.81), ONCS: 5.75 (-0.06), CVRS: 3.59 (-0.18), EGRX: 85.26 (+4.84), CASI: 1.70 (+0.05), PCRX: 67.54 (+0.20), BLRX: 2.29 (+0.05)
OncoSec Medical Incorporated: The Best Immuno-Oncology Biotech You've Never Heard Of
Stock Doctor - Seeking Alpha - Wed Jun 24, 10:39AM CDT
My investment strategy is simple. Find small-cap undervalued biotech companies with promising drugs and significant short and long term upside. My last article published a couple weeks ago detailed Tokai Pharmaceuticals (NASDAQ: TKAI ) and why its...
MRK: 57.95 (+0.57), ONCS: 5.75 (-0.06), BMY: 69.27 (+1.38)
OncoSec Medical Issues Annual Letter To Shareholders
PR Newswire - Wed Jun 17, 3:50PM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today issued the following letter from Punit Dhillon, President and CEO of OncoSec, to the company's shareholders. The letter and supplemental proxy information are available by clicking here. ONCS: 5.75 (-0.06)
OncoSec Medical Enrolls First Patient in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial
PR Newswire - Tue Jun 16, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse(TM) IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC). ImmunoPulse(TM) IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to promote an anti-tumor immune response. ONCS: 5.75 (-0.06)
OncoSec Medical Set to Join Russell Microcap Index
PR Newswire - Mon Jun 15, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it is set to join the Russell Microcap Index at the conclusion of the Russell indexes annual reconstitution on June 26, according to a preliminary list of additions posted on June 12. ONCS: 5.75 (-0.06)
OncoSec Medical incurs higher net loss of USD14.7m for nine months fiscal year end 2015
M2 - Wed Jun 10, 3:48AM CDT
Cancer immunotherapies company OncoSec Medical (NasdaqCM:ONCS) stated on Monday its net loss of USD14.7m (USD1.19 per share) for the nine months ended 30 April 2015.
ONCS: 5.75 (-0.06)
OncoSec Medical reports 9M15 results
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 5:25AM CDT
ONCS: 5.75 (-0.06)
OncoSec Medical reports Q1 results
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 5:06AM CDT
ONCS: 5.75 (-0.06)
OncoSec Medical Announces Nine Months Results for Fiscal Year End 2015
PR Newswire - Tue Jun 09, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015. ONCS: 5.75 (-0.06)
OncoSec Medical concludes USD13.6m in registered direct offering
M2 - Tue Jun 09, 4:40AM CDT
Biopharmaceutical company OncoSec Medical (NasdaqCM:ONCS) reported on Monday the completion of its registered direct offering of 2,469,091 shares of its common stock.
ONCS: 5.75 (-0.06)
OncoSec Medical Closes $13.6 Million Registered Direct Offering
PR Newswire - Mon Jun 08, 4:27PM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced registered direct offering of 2,469,091 shares of its common stock at a price of $5.50 per share on June 8, 2015. ONCS: 5.75 (-0.06)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
OncoSec Medical to Present at the BIO International Convention
PR Newswire - Thu Jun 04, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at the BIO International Convention on Wednesday, June 17 in Philadelphia. The presentation is scheduled to begin at 11:15 AM ET in Theater 4 at the Pennsylvania Convention Center. ONCS: 5.75 (-0.06)
OncoSec Medical anticipates USD13.6m from registered direct offering
M2 - Thu Jun 04, 3:12AM CDT
OncoSec Medical (NasdaqCM:ONCS), a biopharmaceutical company developing its investigational ImmunoPulseTM intratumoral cancer immunotherapy, announced on Wednesday that it has entered into definitive agreements to raise about USD13.6m of securities in a registered direct offering.
ONCS: 5.75 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 11:45AM CDT
JRJC: 4.74 (-0.01), GLMD: 10.04 (+0.18), ESI: 3.81 (+0.04), LPTH: 1.90 (-0.01), GEVO: 2.71 (+0.26), ARDX: 17.67 (+1.21), VLTC: 4.77 (+0.11), MIND: 4.14 (-0.03), VISN: 11.82 (+1.83), EMITF: 1.35 (+0.02), STDY: 4.97 (+0.21), CPXX: 2.13 (+0.01), PXLW: 5.53 (+0.20), NOR: 0.52 (-0.07), FWM: 3.29 (-0.03), HTGM: 11.64 (-0.14), ONCS: 5.75 (-0.06), CBAY: 2.68 (-0.01), BLFS: 2.00 (-0.03), HQCL: 14.33 (-0.01)
OncoSec Medical Announces $13.6 Million Registered Direct Offering
PR Newswire - Wed Jun 03, 8:42AM CDT
OncoSec Medical Inc. ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has entered into definitive agreements with dedicated healthcare institutional investors to purchase approximately $13.6 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 2,469,091 shares of its common stock at a price of $5.50 per share. ONCS: 5.75 (-0.06)
